Drug Trial Radar · NCT07138001
Phase 2 Clinical Trial of KH617
Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Aug 2025
Primary completion
Sep 2027
Study completion Dec 2030
Sponsor
- Lead sponsor
- Sichuan Honghe Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of KH617 for injection in combination with temozolomide versus investigator's choice therapy or KH617 monotherapy for recurrent glioblastoma
Conditions
- Recurrent Glioblastoma
Interventions
KH617+TMZCombination product
use KH617 and TMZ(5/28) as Combination Product.
KH617Drug
Single Clinical trial investigational drug
TPC: TMZ or Platinum (cisplatin or carboplatin)+VP-16Drug
Comparator product, Two treatment options for physicians and subjects to choose from: 1. use TMZ(7/7) 2. Use Platinum (cisplatin or carboplatin)+VP-16
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: 54 weeks
- PFS-6Time frame: 54 weeks
- TEAETime frame: 54 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.